Alkermes plc Stock
Alkermes plc Stock
Alkermes plc shows a slight decrease today, losing -€0.250 (-0.590%) compared to yesterday.
The stock is one of the favorites of our community with 23 Buy predictions and 1 Sell predictions.
As a result the target price of 46 € shows a slightly positive potential of 8.93% compared to the current price of 42.23 € for Alkermes plc.
Pros and Cons of Alkermes plc in the next few years
Pros
?
B****
?
C******** o* t** e**********
?
M***** P*******
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Alkermes plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Alkermes plc | -0.590% | -1.397% | -7.066% | 84.130% | 79.449% | 66.732% | 75.000% |
| Icon plc | -0.240% | 5.435% | -2.777% | 5.435% | -7.357% | -39.174% | - |
| United Therapeutics | 0.340% | -0.800% | -6.885% | 72.317% | 4.447% | 105.384% | 155.029% |
| Ligand Pharmaceuticals | 1.560% | -4.580% | -9.420% | 96.850% | 50.602% | 296.825% | 166.923% |
Comments
Alkermes (ALKS) had its "overweight" rating reaffirmed by Piper Sandler.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its price target raised by Needham & Company LLC from $61.00 to $62.00. They now have a "buy" rating on the stock.
Show more
Ratings data for ALKS provided by MarketBeat
Alkermes (ALKS) had its "overweight" rating reaffirmed by Wells Fargo & Company.
Show more
Ratings data for ALKS provided by MarketBeat
News
Alkermes Q2 Earnings Call Highlights
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes reported strong Q2 performance: Revenue reached $496 million, while proprietary product sales rose 34% year
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears
Key Points
- Interested in Alkermes plc? Here are five stocks we like better.
- Alkermes’ lead orexin agonist, alixorexton, has entered Phase 3 with the Brilliance program now enrolling in